Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

OBJECTIVE: To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19). DESIGN: Randomised, open label trial. SETTING: Nine hospitals in Brazil, 8 May to 17 July 2020. PARTICIPANTS: Adults with confirmed covid-19 who were recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Veiga, Viviane C, Prats, João A G G, Farias, Danielle L C, Rosa, Regis G, Dourado, Leticia K, Zampieri, Fernando G, Machado, Flávia R, Lopes, Renato D, Berwanger, Otavio, Azevedo, Luciano C P, Avezum, Álvaro, Lisboa, Thiago C, Rojas, Salomón S O, Coelho, Juliana C, Leite, Rodrigo T, Carvalho, Júlio C, Andrade, Luis E C, Sandes, Alex F, Pintão, Maria C T, Castro, Claudio G, Santos, Sueli V, de Almeida, Thiago M L, Costa, André N, Gebara, Otávio C E, de Freitas, Flávio G Rezende, Pacheco, Eduardo S, Machado, David J B, Martin, Josiane, Conceição, Fábio G, Siqueira, Suellen R R, Damiani, Lucas P, Ishihara, Luciana M, Schneider, Daniel, de Souza, Denise, Cavalcanti, Alexandre B, Scheinberg, Phillip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815251/
https://www.ncbi.nlm.nih.gov/pubmed/33472855
http://dx.doi.org/10.1136/bmj.n84

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815251/
https://www.ncbi.nlm.nih.gov/pubmed/33472855
http://dx.doi.org/10.1136/bmj.n84

Ejemplares similares